The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The impact of the approval of pirtobrutinib on the treatment landscape for patients with CLL
Ryan Jacobs, MD, Atrium Health Levine Cancer Institute, Charlotte, NC, discusses the impact of the recent approval of pirtobrutinib, a third-generation BTK inhibitor (BTKi), as a third-line treatment for chronic lymphocytic leukemia (CLL). Dr Jacobs highlights that this was a setting in which patients lacked safe and effective treatment options. Pirtobrutinib is well-tolerated and effective compared to other agents tested in this space, such as duvelisib, a PI3 kinase inhibitor. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I’ve been very excited to have commercial approval for pirtobrutinib in the United States that came earlier this year. Of course, a lot of us had been getting away with using it off-label when we needed it, because it was commercially available in mantle cell for some time previous to this approval. But it’s nice to not have to ask permission from the insurance companies to have the on-label approval...
I’ve been very excited to have commercial approval for pirtobrutinib in the United States that came earlier this year. Of course, a lot of us had been getting away with using it off-label when we needed it, because it was commercially available in mantle cell for some time previous to this approval. But it’s nice to not have to ask permission from the insurance companies to have the on-label approval.
It is sort of firmly rooted right now based on its label in the third line plus space, but that is a space where patients were lacking really safe and effective treatment options. Historically, we had been thinking about PI3 kinase inhibitors like duvelisib in this area, but pirtobrutinib certainly appears to be better tolerated, incredibly low discontinuation rates due to toxicity. And although it doesn’t give us the long progression-free survivals that we see with, say, first-line BTK inhibition, it is now a really good third-line option for our CLL patients that have needs beyond covalent BTK and BCL2 inhibition.
Read more...
